Your browser is no longer supported. Please, upgrade your browser.
Settings
AXON Axovant Sciences Ltd. daily Stock Chart
AXON [NYSE]
Axovant Sciences Ltd.
Index- P/E- EPS (ttm)-1.83 Insider Own0.60% Shs Outstand105.81M Perf Week15.83%
Market Cap2.54B Forward P/E- EPS next Y-2.97 Insider Trans101.95% Shs Float32.39M Perf Month4.76%
Income-181.00M PEG- EPS next Q-0.54 Inst Own26.10% Short Float11.02% Perf Quarter62.71%
Sales- P/S- EPS this Y-29.50% Inst Trans2.16% Short Ratio4.73 Perf Half Y88.68%
Book/sh1.68 P/B14.29 EPS next Y-40.80% ROA- Target Price28.81 Perf Year111.27%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range11.01 - 25.18 Perf YTD93.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-4.69% Beta-
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low117.98% ATR1.30
Employees69 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)59.31 Volatility6.30% 6.00%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.94 Prev Close23.80
ShortableYes LT Debt/Eq0.00 EarningsJun 19 Payout- Avg Volume755.22K Price24.00
Recom1.90 SMA208.43% SMA507.00% SMA20052.12% Volume711,931 Change0.84%
Jun-14-17Reiterated Oppenheimer Outperform $26 → $30
Dec-20-16Initiated Laidlaw Sell $7.50
Dec-07-16Initiated Oppenheimer Outperform $20
Jun-07-16Initiated Leerink Partners Outperform $22
Jan-08-16Initiated H.C. Wainwright Buy $35
Oct-22-15Initiated Piper Jaffray Overweight
Sep-25-15Reiterated Chardan Capital Markets Sell $9.50 → $8
Jul-15-15Initiated JMP Securities Mkt Outperform $36
Jul-13-15Initiated Robert W. Baird Outperform $29
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Jul-06-15Initiated Jefferies Buy $31
Jun-18-15Initiated Chardan Capital Markets Sell $10
Jun-20-17 08:15AM  Featured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial at the IMCL Conference in Switzerland Accesswire +7.43%
Jun-19-17 08:43AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
07:00AM  FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies PR Newswire
Jun-14-17 04:42PM  Rigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data Benzinga
Jun-13-17 07:15AM  Axovant reports 4Q loss Associated Press
07:00AM  Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates PR Newswire
Jun-06-17 07:30AM  Axovant Strengthens Executive Team with Key Management Appointments PR Newswire
07:30AM  Axovant Announces Changes to Board of Directors PR Newswire
May-31-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Apr-18-17 03:43PM  Axovant: A New CEO Doesn't Change Anything Motley Fool
Apr-17-17 04:15PM  Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares PR Newswire
Apr-13-17 12:21PM  Shark Bites: You Don't Want to Play the Gambler Today TheStreet.com +11.11%
Apr-12-17 08:37AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
08:20AM  Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2% Zacks
Apr-11-17 04:29PM  What's Got Axovant Sciences Jumping 10% Today? Motley Fool +9.22%
02:55PM  New Captain, Same Ship for Axovant Bloomberg
07:30AM  Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Accesswire
07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
07:00AM  Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares PR Newswire
06:00AM  The State of Play in Axovant Sciences Investopedia
12:20AM  [$$] The $400 Million Man The Wall Street Journal
Apr-10-17 04:30PM  Axovant CEO David Hung Promises To Invest $10 Million As Company Moves To Raise $100 Million Forbes +22.54%
04:15PM  Biotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives Investor's Business Daily
04:05PM  Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares PR Newswire
01:50PM  Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk TheStreet.com
01:46PM  Why Axovant Sciences Is Soaring 25% Today Motley Fool
12:12PM  [$$] Axovant shares jump after Medivation founder named chief Financial Times
11:40AM  [$$] The $400 Million Man The Wall Street Journal
11:39AM  Axovant stock surges 28% on new CEO MarketWatch
11:18AM  A company developing a drug to treat Alzheimer's disease just got a new CEO and the stock is jumping Business Insider
10:00AM  Medivation Founder Takes Helm at Axovant, Shares Spike TheStreet.com
08:15AM  Medivation Founder David Hung Becomes CEO Of Axovant Sciences Forbes
08:15AM  Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors PR Newswire
Mar-21-17 04:30PM  Axovant Sciences to Present at Upcoming Scientific Meetings PR Newswire
Mar-20-17 04:35PM  Axovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference PR Newswire
Mar-17-17 08:30AM  Is the Options Market Predicting a Spike in Axovant Sciences (AXON) Stock? Zacks
Feb-27-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire +7.59%
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? Motley Fool
05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-18-17 01:04PM  AXOVANT SCIENCES LTD. Financials
Feb-15-17 07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? Motley Fool
07:34PM  Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? at Motley Fool
11:15AM  [$$] Merck's drug failure deals further blow to Alzheimer's theory at Financial Times
Feb-14-17 05:54PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
05:31PM  Axovant reports 3Q loss Associated Press
04:15PM  Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016 PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
Feb-13-17 09:19AM  Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More -6.47%
07:07AM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Other Events
07:00AM  Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients PR Newswire
Feb-08-17 11:35AM  Axovant Rival's Alzheimer Drug Fails Study at Investopedia
Feb-03-17 05:18PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial +14.38%
07:00AM  Axovant Sciences Announces $55.0 Million Venture Debt Financing from Hercules Capital PR Newswire
Jan-25-17 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Jan-09-17 07:11AM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:00AM  Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference PR Newswire
Dec-28-16 08:55AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
Dec-20-16 09:06AM  Coverage initiated on Axovant Sciences by Laidlaw
Dec-09-16 04:15PM  Axovant Unveils New Data Analysis Showing Addition of Intepirdine to Standard Therapy May Help People with Alzheimer's Disease Maintain Independence Longer PR Newswire
Dec-08-16 03:29PM  Is Axovant Sciences Ltd (AXON) Worthy of Your Portfolio? at Insider Monkey
Dec-05-16 04:30PM  Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016 PR Newswire
Nov-28-16 02:12PM  Axovant Sciences Ltd. :AXON-US: Earnings Analysis: Q2, 2017 By the Numbers : November 28, 2016
Nov-25-16 07:00AM  Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
Nov-23-16 05:01PM  Eli Lilly's Alzheimer's Drug Is a Bust at Motley Fool
02:49PM  Five Lessons From Today's Pharma Failures at Forbes
11:41AM  Another failure in search for treatment to slow Alzheimer's
08:41AM  Trending Stocks: First Solar, Inc. (FSLR), Eli Lilly and Co (LLY), and More at Insider Monkey
Nov-08-16 04:24PM  Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's? -7.24%
Nov-07-16 06:40PM  Axovant reports 2Q loss +6.65%
04:58PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:15PM  Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016 PR Newswire
Nov-01-16 04:30PM  Axovant Sciences to Present at Upcoming Investor Conferences PR Newswire
Oct-27-16 08:56AM  Biggest Biotech IPO Of 2016 Is Launched By 31 Year Old at Forbes
Oct-25-16 04:32PM  Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
Oct-20-16 07:51AM  Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma
Oct-19-16 04:01PM  Patrick Machado Joins Board of Directors of Roivant Sciences PR Newswire
Sep-26-16 08:00AM  Axovant Sciences Receives FDA Fast-Track Designation for Intepirdine as an Investigational Treatment for Dementia with Lewy Bodies PR Newswire
Sep-23-16 04:07PM  Axovant Confidence 'Not Swayed' After Rival Alzheimer's Drug Fails
Sep-22-16 06:09PM  Axovant shares slammed after rival Alzheimer's treatment data disappoints at CNBC -12.49%
03:33PM  Lundbeck says Alzheimer's drug fails in late-stage study Reuters
02:12PM  Axovant Sciences (AXON) Stock Slumps, Baird: Weakness 'Unwarranted'
Sep-21-16 08:00AM  Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer's Disease PR Newswire
Sep-13-16 03:15PM  Axovant Sciences Ltd. :AXON-US: Earnings Analysis: Q1, 2017 By the Numbers : September 13, 2016
Sep-06-16 04:30PM  Axovant Sciences to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Aug-31-16 04:30PM  Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference PR Newswire
Aug-22-16 04:19PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Aug-17-16 09:33AM  RA Capitals Top Q2 Performers; Predicts Big Things Ahead for Pharma Stocks at Insider Monkey
Aug-16-16 03:15PM  Axovant Sciences' Earnings Miss Takes A Backseat To Expected Pipeline Expansion
Aug-15-16 04:52PM  Axovant reports 1Q loss
04:36PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:15PM  Axovant Sciences Announces Expansion of Dementia Pipeline and Reports Financial Results for the First Fiscal Quarter Ended June 30, 2016 PR Newswire
Jul-24-16 08:00AM  Alzheimer's Experts Call for End to Under-Treatment of Disease PR Newswire
Jul-19-16 12:21AM  Companies Try New Ways to Attract Patients to Drug Trials at The Wall Street Journal
Jul-18-16 04:30PM  Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference PR Newswire
Jul-14-16 07:20PM  Halvorsen Funds Company Buying Neglected Drugs, Gets Stakes in 2 Biotechs
02:06PM  Andreas Halvorsen Invests in Axovant Sciences
Jul-13-16 04:01PM  Roivant Sciences Appoints Professor Andrew Lo, PhD as Independent Director PR Newswire
Jul-06-16 05:13PM  AXOVANT SCIENCES LTD. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exh
Jun-29-16 02:52PM  These companies hope to deliver a blockbuster Alzheimers drug
Jun-15-16 10:30AM  Axovant Sciences to Present at the JMP Securities Life Sciences Conference PR Newswire
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VERNON W ANTHONYDirectorApr 17Buy18.5453,937999,99253,937Apr 19 04:08 PM
FALBERG KATHRYN EDirectorApr 17Buy18.5453,937999,99253,937Apr 19 04:07 PM
Hung DavidPrincipal Executive OfficerApr 17Buy18.54539,37510,000,013539,375Apr 19 04:06 PM